Big 4 Private Equity Firms In Brighter Mood; Falling Investment In Biotech
Private equity fundraising struggled in 2024, with total capital raised declining for the third consecutive year. Read more ...
Proposal to implement year-round Pacific Standard Time in Washington among bills that appear dead
A proposal backed by Gov. Bob Ferguson to increase student access to free meals served at public schools also appears dead, at least for now.
Bluebird Bio to Be Acquired by Carlyle Group, SK Capital
Cash-strapped gene-therapy company Bluebird bio agreed to be acquired by private-equity firms Carlyle Group and SK Capital Partners in a deal potentially worth up to $96 million.
Ariel Investments Small/Mid Cap Value Q4 2024 Commentary
Markets worldwide defied expectations in 2024 led by the dominating performance of mega-cap technology stocks known as the ...
Lawmakers reach first major deadline in legislative session
Former Washington state Sen. Reuven Carlyle breaks down which bills are safe and which are on the chopping block,.
Struggling Somerville biotech Bluebird Bio to be sold for less than $30 million
Bluebird Bio announced Friday it would sell itself and its portfolio of gene therapies to the investment firms Carlyle and SK ...
The Aspen Times18h
Mountain Mayhem: Bemelmans Bar x Mytheresa take Aspen
For the very first time, the storied Bemelmans Bar within The Carlyle, A Rosewood Hotel, has popped up outside of its Upper ...
Pacers' Rick Carlisle Sends Message to NBA Following Myles Turner Return
The Pacers center had a big night against the Grizzlies and Carlisle had a message for the rest of the league.
NBC Los Angeles23h
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Bluebird Bio will sell itself to private equity firms Carlyle and SK Capital for about $30 million, the company said Friday.